Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
Authors:
- 2 October 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 79 (14) , 1428-1434
Abstract
Objective: To compare the cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in patients with atrial fibrillation (AF). Methods: Using standard methods, we created a Markov decision model based on the estimated cost of apixaban and data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial and other trials of warfarin therapy for AF. We quantified the cost and quality-adjusted life expectancy resulting from apixaban 5 mg twice daily compared with those from warfarin therapy targeted to an international normalized ratio of 2–3. Our base case population was a cohort of 70-year-old patients with no contraindication to anticoagulation and a history of stroke or TIA from nonvalvular AF. Results: Warfarin therapy resulted in a quality-adjusted life expectancy of 3.91 years at a cost of $378,500. In comparison, treatment with apixaban led to a quality-adjusted life expectancy of 4.19 years at a cost of $381,700. Therefore, apixaban provided a gain of 0.28 quality-adjusted life-years (QALYs) at an additional cost of $3,200, resulting in an incremental cost-effectiveness ratio of $11,400 per QALY. Our findings were robust in univariate sensitivity analyses varying model inputs across plausible ranges. In Monte Carlo analysis, apixaban was cost-effective in 62% of simulations using a threshold of $50,000 per QALY and 81% of simulations using a threshold of $100,000 per QALY. Conclusions: Apixaban appears to be cost-effective relative to warfarin for secondary stroke prevention in patients with AF, assuming that it is introduced at a price similar to that of dabigatran.Keywords
This publication has 28 references indexed in Scilit:
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic AttackStroke, 2012
- Acutely Injured Patients on DabigatranNew England Journal of Medicine, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial FibrillationCirculation, 2011
- Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: Results from the Treating to New Targets (TNT) TrialAmerican Heart Journal, 2008
- The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registryAmerican Heart Journal, 2006
- Selecting Patients With Atrial Fibrillation for AnticoagulationCirculation, 2004
- Risk Factors for Intracerebral Hemorrhage in the General PopulationStroke, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996